[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"electronic-cigarette-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:electronic-cigarette-use":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,74,100,123,144,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100432132","developing-and-testing-health-warning-labels-on-the-ends-device-100432132",false,"NCT04907136","Developing and Testing Health Warning Labels on the ENDS Device","Inclusion Criteria:\n\n* Generally healthy individuals (determined by physical examination).\n* Age of 21-35 years.\n* Is willing to provide informed consent.\n* Is willing to attend the lab as required by the study protocol.\n* ENDS users (defined as using ENDS either daily or occasionally in the past 30 days)\n* Have abstained from ENDS use for 12 hours prior to each session.\n\nExclusion Criteria:\n\n* Report smoking cigarettes regularly (\\> 5 cigarettes\u002Fmonth in the past year).\n* Report regular use of any other tobacco\u002Fnicotine product (e.g., e-cig, pipes, cigars) in the past year.\n* Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).\n* Individuals with self-reported history of chronic disease or psychiatric conditions.\n* Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).\n* Individuals that report the use of non-commercial (i.e., street) e-cigarette liquid or products\n* Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)\n* Individuals that have or have been exposed to COVID-19 in the last 14 days.",true,"ALL","21 Years","35 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this project, after systematically developing electronic nicotine delivery systems (ENDS) pictorial health warning labels (HWLs), a proven clinical lab model will be used to examine and test their effect when these are placed on the ENDS device on a variety of subjective (e.g. satisfaction, harm perception, nicotine dependence, intention to quit) and objective outcomes (e.g. plasma nicotine, puff topography) in young adults.",[27],"Electronic Cigarette Use",[29],"Health Warning Labels","RECRUITING","2026-06-04",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":34},"2023-12-13",{"date":38,"type":21},"2027-04-30",{"name":40,"class":41},"Florida International University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100562895","phase-1-effect-of-cannabis-on-e-cigarette-use-behavior-100562895","NCT06609109","Effect of Cannabis on E-Cigarette Use Behavior","Effect of Cannabinoids on Tobacco Product Demand and Pharmacodynamics: Electronic Cigarette Use","Inclusion criteria:\n\n1. Healthy non-treatment seeking adults aged 21 or older\n2. Report daily use of e-cigarettes\n3. Biological confirmation of e-cigarette use: have a positive urine cotinine test at screening\n4. Report current use of cannabis (at least 1 occasion per week)\n5. Have experience with the inhalation route of administration for cannabis\n6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening.\n7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study.\n\nExclusion criteria:\n\n1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days\n2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine\n3. Test positive for illicit drugs other than cannabis and tobacco\n4. Positive breath alcohol test at study admission\n5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity\n6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)\n7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding\n8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)\n9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":51,"type":21},100,[53],"PHASE1","The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.",[56,57,27],"Cannabis Use","Tobacco Use",[59,60,61,62,63,64],"cannabis","e-cigarette","electronic cigarette","marijuana","THC","Tobacco","2026-04-08",{"date":67,"type":34},"2026-04-09",{"date":69,"type":34},"2025-03-19",{"date":71,"type":21},"2029-10-01",{"name":73,"class":41},"Johns Hopkins University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100552531","phase-4-the-avenues-study-dual-use-cessation-100552531","NCT06474299","The Avenues Study: Dual Use Cessation","Dual Use Cessation: A MOST Screening Trial to Identify Effective Interventions to Help People Who Smoke and Vape","Inclusion Criteria:\n\n* Able to read and communicate in English\n* Willing to set a quit date to quit smoking cigarettes in the next 30 days\n* Willing and medically able to use varenicline and nicotine patches\n* Smoking ≥ 5 cigarettes per day for the past 6 months\n* Vaping weekly for at least 6 months\n* Willing to stop using nicotine replacement or varenicline\n* Willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation\n* Saliva cotinine \\>20 ng\u002Fml\n* US resident\n* Own a Smartphone to use and download an app to record data\n* have a working email so that they can receive links for video visits\n\nExclusion Criteria:\n\n* Currently in treatment for psychosis or bipolar disorder\n* If they are currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)\n* Currently pregnant or breastfeeding. If a participant becomes pregnant while in the study, they will be allowed to continue in the study but will no longer receive study medications. They will also be asked to return any unused study medications.",{"count":82,"type":21},500,[84],"PHASE4","The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.",[87,27],"Smoking Cessation",[89,90],"ENDS","Cessation","2026-04-07",{"date":93,"type":34},"2026-04-13",{"date":95,"type":34},"2024-09-24",{"date":97,"type":21},"2028-07",{"name":99,"class":41},"University of Wisconsin, Madison",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":42},"100465291","effect-of-menthol-on-ends-users-addiction-and-exposure-100465291","NCT05338801","Effect of Menthol on ENDS Users' Addiction and Exposure","The Effect of Menthol on ENDS Users' Dependence, Respiratory, and Toxicants Emission Outcomes.","Inclusion Criteria:\n\n* Generally healthy individuals (determined by physical examination).\n* Age of 21-35 years.\n* Is willing to provide informed consent.\n* Is willing to attend the lab as required by the study protocol.\n* E-cigarette users (defined as using e-cigarette either daily or occasionally in the past 30 days)\n* Have abstained from e-cigarette use for 12 hours prior to each session\n\nExclusion Criteria:\n\n* Report smoking cigarettes regularly (\\> 5 cigarettes\u002Fmonth in the past year).\n* Report regular use of any other tobacco\u002Fnicotine product (e.g., e-cig, pipes, cigars) in the past year.\n* Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).\n* Individuals with self-reported history of chronic disease or psychiatric conditions.\n* Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).\n* Individuals that report current THC (marijuana) smoking\u002Fvaping.\n* Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)\n* Individuals that have or have been exposed to COVID-19 in the last 14 days.",{"count":108,"type":21},250,[24],"The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS \"pod mods\" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current\u002Fpast month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensive assessment of the pros and cons of regulating mentholated ENDS for different segments of the society. Such evidence will help advance FDA regulatory policies with the potential to reduce ENDS harm.",[27],[113,114],"Menthol Flavor","Tobacco Flavor","2026-03-31",{"date":117,"type":34},"2026-04-01",{"date":119,"type":34},"2022-06-22",{"date":121,"type":21},"2027-03-31",{"name":40,"class":41},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":42},"100563028","effects-of-e-cigarette-use-on-health-100563028","NCT06610838","Effects of E-cigarette Use on Health","Longitudinal Effects of E-cigarette Use on Cardiovascular and Pulmonary Health","VAPECHECK","Inclusion Criteria:\n\n* greater than or equal to 21 years of age\n* has vaped a nicotine e-cigarette product at least 2 days\u002Fweek for most weeks for greater than or equal to 12 months\n* plans to remain in catchment area for greater than or equal to 3 years\n* smoked 5 or fewer tobacco cigarettes in the past 6 months\n* no serious CV, pulmonary, or other medical problems\n* not currently pregnant\n* no plans to stop vaping\n\nExclusion Criteria:\n\n* serious CV, pulmonary, or other medical problems (e.g., moderate or severe aortic stenosis, class III or IV heart failure, blood pressure greater than or equal to 160\u002F100 mmHg, interstitial lung disease, sarcoidosis, Stage 3 or 4 cancer)\n* combusted or vaped cannabis use 3 days\u002Fweek or more in the past 3 months\n* currently pregnant\n* not able to read an write English\n* incarceration",{"count":132,"type":21},600,"OBSERVATIONAL","Electronic nicotine delivery systems (ENDS) are used by millions of Americans, however their long-term health effects are unknown. This research proposal will quantify the effects of long-term ENDS use on validated and novel biomarkers of cardiovascular and pulmonary disease and how they are influenced by use heaviness, age, body weight, and co-use of other products. This study will produce the most informative evidence to date on how long-term ENDS use affects cardiovascular and pulmonary health.",[27],"2025-12-23",{"date":138,"type":34},"2025-12-24",{"date":140,"type":34},"2025-01-06",{"date":142,"type":21},"2029-06-30",{"name":99,"class":41},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":15,"sex":16,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100553681","early-phase-1-role-of-inflammation-in-vascular-phenotype-associated-with-e-cigarette-use-100553681","NCT06489249","Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use","Inclusion Criteria:\n\n* 18 - 24 years of age\n* no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).\n\nExclusion Criteria:\n\n* tobacco cigarette use (current or history of)\n* use of stimulant drugs\n* skin diseases\n* cardiovascular disease\n* diagnosed or suspected hepatic or metabolic disease including diabetes\n* statin or other cholesterol-lowering medication\n* antihypertensive medication\n* current pregnancy or breastfeeding\n* blood pressure greater than or equal to 140mmHg systolic and\u002For greater than or equal to 90mmHg diastolic\n* allergy to materials used during the experiment\n* known allergies to salsalate or other study drugs","18 Years","24 Years",{"count":153,"type":21},24,[155],"EARLY_PHASE1","The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as \"vaping\" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.",[27,158,159],"Endothelial Dysfunction","Inflammation","2025-12-08",{"date":162,"type":34},"2025-12-15",{"date":164,"type":34},"2024-08-15",{"date":166,"type":21},"2026-10",{"name":168,"class":41},"University of Iowa",2,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":15,"sex":16,"minAge":150,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":42},"100538496","vaping-adverse-lung-and-heart-events-cohort-100538496","NCT06291597","Vaping Adverse Lung and Heart Events Cohort","VapALERT: A Prospective, Exploratory and Adaptive Cohort Study to Identify Symptomatic and Asymptomatic Pulmonary and Cardiovascular Effects of Vaping","VapALERT","Inclusion Criteria:\n\n* Age 18 years or older\n* Daily electronic cigarette user\n* No respiratory infection in the 4 weeks before a visit\n\nExclusion Criteria:\n\n* Women who are pregnant or breast-feeding.",{"count":108,"type":21},"This prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.",[181,27],"Vaping",[181,183,184,185,186],"Vape","Electronic cigarette","Electronic and vaping acute lung injury","EVALI","2024-02-26",{"date":189,"type":34},"2024-03-04",{"date":191,"type":34},"2021-10-14",{"date":193,"type":21},"2032-06",{"name":195,"class":41},"Laval University"]